Leading-edge myofibroblasts in human colon cancer express plasminogen activator inhibitor-1

American Journal of Clinical Pathology

Volumn 122, Issue 2, 2004, Pages 256-265

  Illemann, Martin ^a   Hansen, Ulla ^b   Nielsen, Hans Jørgen ^a,b   Andrease, Peter A ^c   Høyer Hansen, Gunilla ^a   Lund, Leif R ^a   Danø, Keld ^a   Nielsen, Boye Schnack ^a  

^a FINSEN LABORATORY   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

Colon cancer; Immunohistochemistry; In situ hybridization; Myofibroblasts; PAI 1; Plasminogen activator inhibitor 1

Indexed keywords

ALPHA ACTIN; CD34 ANTIGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER TISSUE; COLON ADENOCARCINOMA; COLON CANCER; ENDOTHELIUM CELL; FEMALE; FIBROBLAST; GENE EXPRESSION; GENE LOCATION; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INVASIVE CARCINOMA; MALE; MYOFIBROBLAST; PRIORITY JOURNAL; RECTUM CARCINOMA; SMOOTH MUSCLE FIBER;

EID: 3242753364     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/F32XWQ20T568H8VP     Document Type: Article

References (35)

1. Dano K, Andreasen PA, Grondahl-Hansen J, et al. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139-266.
2. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci. 2000;57:25-40.
3. Ellis V, Behrendt N, Dano K. Plasminogen activation by receptor-bound urokinase: a kinetic study with both cell-associated and isolated receptor. J Biol Chem. 1991;266:12752-12758.
4. Ronne E, Behrendt N, Ellis V, et al. Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor. FEBS Lett. 1991;288:233-236.
5. Behrendt N, List K, Andreasen PA, et al. The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation. Biochem J. 2003;371:277-287.
6. Duffy MJ, Reilly D, O'Sullivan C, et al. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res. 1990;50:6827-6829.
7. Grondahl-Hansen J, Christensen IJ, Rosenquist C, et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 1993;53:2513-2521.
8. Pedersen H, Brünner N, Francis D, et al. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res. 1994;54:4671-4675.
9. Nielsen HJ, Pappot H, Christensen IJ, et al. Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer. BMJ. 1998;316:829-830.
10. Stephens RW, Nielsen HJ, Christensen IJ, et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst. 1999;91:869-874.
11. Grondahl-Hansen J, Ralfkiær E, Kirkeby LT, et al. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol. 1991;138:111-117.
12. Pyke C, Kristensen P, Ralfkiær E, et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol. 1991;138:1059-1067.
13. Pyke C, Ralfkiær E, Ronne E, et al. Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathology. 1994;24:131-138.
14. Pyke C, Salo S, Ralfkiaer E, et al. Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. Cancer Res. 1995;55:4132-4139.
15. Pyke C, Kristensen P, Ralfkiaer E, et al. The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res. 1991;51:4067-407 1.
16. Offersen BV, Nielsen BS, Hoyer-Hansen G, et al. The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas. Am J Pathol. 2003;163:1887-1899.
17. 2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor. Biochem J. 1998;329:55-63.
18. Nielsen BS, Rank F, Lopez JM, et al. Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas. Cancer Res. 2001;61:7091-7100.
19. Sappino AP, Dietrich PY, Skalli O, et al. Colonic pericryptal fibroblasts: differentiation pattern in embryogenesis and phenotypic modulation in epithelial proliferative lesions. Virchows Arch A Pathol Anat Histopathol. 1989;415:551-557.
20. Adegboyega PA, Mifflin RC, DiMari JF, et al. Immunohistochemical study of myofibroblasts in normal colonic mucosa, hyperplastic polyps, and adenomatous colorectal polyps. Arch Pathol Lab Med. 2002;126:829-836.
21. Koretz K, Möller P, Schwartz-Albiez R. Plasminogen activators and plasminogen activator inhibitors in human colorectal carcinoma tissues are not expressed by the tumour cells. Eur J Cancer. 1993;29A:1184-1189.
22. Naitoh H, Eguchi Y, Ueyama H, et al. Localization of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, 2 and plasminogen in colon cancer. Jpn J Cancer Res. 1995;86:48-56.
23. Kaye GI, Lane N, Pascal RR. Colonic pericryptal fibroblast sheath: replication, migration, and cytodifferentiation of a mesenchymal cell system in adult tissue, II: fine structural aspects of normal rabbit and human colon. Gastroenterology. 1968;54:852-865.
24. Sappino AP, Skalli O, Jackson B, et al. Smooth-muscle differentiation in stromal cells of malignant and non-malignant breast tissues. Int J Cancer. 1988;41:707-712.
25. Ronnov-Jessen L, Petersen OW, Koteliansky VE, et al. The origin of the myofibroblasts in breast cancer: recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J Clin Invest. 1995;95:859-873.
26. Powell DW, Mifflin RC, Valentich JD, et al. Myofibroblasts, II: intestinal subepithelial myofibroblasts. Am J Physiol. 1999;277:C183-C201.
27. De Wever O, Mareel M. Role of myofibroblasts at the invasion front. Biol Chem. 2002;383:55-67.
28. Nielsen BS, Sehested M, Timshel S, et al. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab Invest. 1996;74:168-177.
29. Nielsen BS, Sehested M, Duun S, et al. Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer. Lab Invest. 2001;81:1485-1501.
30. Wolf C, Rouyer N, Lutz Y, et al. Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc Natl Acad Sci U S A. 1993;90:1843-1847.
31. Bisson C, Blacher S, Polette M, et al. Restricted expression of membrane type 1-matrix metalloproteinase by myofibroblasts adjacent to human breast cancer cells. Int J Cancer. 2003;105:7-13.
32. Hewitt R, Danø K. Stromal cell expression of components of matrix-degrading protease systems in human cancer. Enzyme Protein. 1996;49:163-173.
33. Bajou K, Noel A, Gerard RD, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med. 1998;4:923-928.
34. Bajou K, Masson V, Gerard RD, et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin: implications for antiangiogenic strategies. J Cell Biol. 2001;152:777-784.
35. Almholt K, Nielsen BS, Frandsen TL, et al. Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice. Oncogene. 2003;22:4389-4397.